Shenzhen Salubris Pharmaceuticals (002294.SZ): Clinical Trial Application for Self-Developed Innovative Small Molecule Drug SAL0140 Tablet Receives Acceptance

Stock News08-28

Shenzhen Salubris Pharmaceuticals Co.,Ltd. (002294.SZ) announced that the company recently received an acceptance notice approved and issued by the National Medical Products Administration. The clinical trial application for the company's independently developed innovative small molecule drug SAL0140 tablet (project code: SAL0140) has been accepted.

SAL0140 is an aldosterone synthase inhibitor with independent intellectual property rights owned by the company. The proposed indications include uncontrolled hypertension (including refractory hypertension) and chronic kidney disease (CKD). Currently, SAL0140 (for uncontrolled hypertension) is in Phase I clinical stage.

If SAL0140 can be successfully developed and approved for market launch, it is expected to provide targeted new medication options for hypertension patients in more subdivided areas and CKD patients, meeting unmet clinical needs and further enriching the company's innovative product pipeline in the chronic disease field.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1183065297?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-28 16:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183065297","market":"other","top_or_hot":-1,"title":"Shenzhen Salubris Pharmaceuticals (002294.SZ): Clinical Trial Application for Self-Developed Innovative Small Molecule Drug SAL0140 Tablet Receives Acceptance","media":"Stock News","content":"<p>Shenzhen Salubris Pharmaceuticals Co.,Ltd. (002294.SZ) announced that the company recently received an acceptance notice approved and issued by the National Medical Products Administration. The clinical trial application for the company's independently developed innovative small molecule drug SAL0140 tablet (project code: SAL0140) has been accepted.</p>\n<p>SAL0140 is an aldosterone synthase inhibitor with independent intellectual property rights owned by the company. The proposed indications include uncontrolled hypertension (including refractory hypertension) and chronic kidney disease (CKD). Currently, SAL0140 (for uncontrolled hypertension) is in Phase I clinical stage.</p>\n<p>If SAL0140 can be successfully developed and approved for market launch, it is expected to provide targeted new medication options for hypertension patients in more subdivided areas and CKD patients, meeting unmet clinical needs and further enriching the company's innovative product pipeline in the chronic disease field.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shenzhen Salubris Pharmaceuticals (002294.SZ): Clinical Trial Application for Self-Developed Innovative Small Molecule Drug SAL0140 Tablet Receives Acceptance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShenzhen Salubris Pharmaceuticals (002294.SZ): Clinical Trial Application for Self-Developed Innovative Small Molecule Drug SAL0140 Tablet Receives Acceptance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-08-28 16:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shenzhen Salubris Pharmaceuticals Co.,Ltd. (002294.SZ) announced that the company recently received an acceptance notice approved and issued by the National Medical Products Administration. The clinical trial application for the company's independently developed innovative small molecule drug SAL0140 tablet (project code: SAL0140) has been accepted.</p>\n<p>SAL0140 is an aldosterone synthase inhibitor with independent intellectual property rights owned by the company. The proposed indications include uncontrolled hypertension (including refractory hypertension) and chronic kidney disease (CKD). Currently, SAL0140 (for uncontrolled hypertension) is in Phase I clinical stage.</p>\n<p>If SAL0140 can be successfully developed and approved for market launch, it is expected to provide targeted new medication options for hypertension patients in more subdivided areas and CKD patients, meeting unmet clinical needs and further enriching the company's innovative product pipeline in the chronic disease field.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"国家队","start_time":0,"source_url":"","article_id":"1183065297","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183065297","pubTimestamp":1756368897,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shenzhen Salubris Pharmaceuticals Co.,Ltd. (002294.SZ) announced that the company recently received an acceptance notice approved and issued by the National Medical Products Administration. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0028":"国家队","BK0239":"医药制造","002294":"信立泰","BK0183":"MSCI概念","BK0188":"融资融券","BK0196":"行业龙头","BK0187":"一线龙头"},"translate_title":"深圳赛百利药业（002294.SZ）：自主研发创新小分子药SAL0140片临床试验申请获受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002294":1},"content_text":"Shenzhen Salubris Pharmaceuticals Co.,Ltd. (002294.SZ) announced that the company recently received an acceptance notice approved and issued by the National Medical Products Administration. The clinical trial application for the company's independently developed innovative small molecule drug SAL0140 tablet (project code: SAL0140) has been accepted.\nSAL0140 is an aldosterone synthase inhibitor with independent intellectual property rights owned by the company. The proposed indications include uncontrolled hypertension (including refractory hypertension) and chronic kidney disease (CKD). Currently, SAL0140 (for uncontrolled hypertension) is in Phase I clinical stage.\nIf SAL0140 can be successfully developed and approved for market launch, it is expected to provide targeted new medication options for hypertension patients in more subdivided areas and CKD patients, meeting unmet clinical needs and further enriching the company's innovative product pipeline in the chronic disease field.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1183065297","isCrawlerRequest":true}